ArticleAmerican journal of translational research2026
Efficacy of immune checkpoint inhibitors combined with chemotherapy for advanced gastric cancer.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects and safety of immune checkpoint inhibitors (ICIs) combined with chemotherapy for advanced gastric cancer, and to evaluate the predictive value of pretreatment peripheral blood inflammatory markers and tumor markers for progression-free survival (PFS).
methodsA retrospective analysis was performed on 89 patients with advanced gastric cancer who received ICI-based treatment. All patients completed at least three cycles of ICI-based treatment. Pretreatment peripheral blood inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and serum carbohydrate antigen 19-9 (CA19-9) levels were collected. Treatment regimens consisted of ICIs combined with chemotherapy, with or without targeted therapy. Tumor response was assessed using contrast-enhanced CT or MRI according to RECIST version 1.1. PFS was analyzed using the Kaplan-Meier method and Cox proportional hazards regression model. ROC curve analysis was conducted to explore the prognostic efficacy of the above biomarkers.
resultsNo patient achieved complete response. Among all cases, 17 patients achieved partial response, 51 had stable disease, and 21 experienced progressive disease. The overall objective response rate (ORR) and disease control rate (DCR) were 19.10% and 76.40%, respectively, with no significant difference between the two treatment groups in ORR or DCR (
conclusionICI combined chemotherapy yields favorable disease control and acceptable safety in patients with advanced gastric cancer. Pretreatment elevated peripheral blood inflammatory markers and CA19-9 levels are associated with poor prognosis, among which SII and CA19-9 were independent risk factors for shortened PFS. Dynamic monitoring of these biomarkers can facilitate clinical risk stratification and individualized treatment decision-making for advanced gastric cancer patients receiving ICI-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.